• Navigation

    • Home
    • About
    • Research
    • Science
    • Pipeline
    • News
    • Contact
  • About
  • Research
  • Science
  • Pipeline
  • News
    • News
    • Press Releases
    • Presentations
    • Publications
  • Contact

Presentations

Diakonos Oncology Presents Promising Phase I Results of Dubodencel (DOC1021) at the ASCO 2025 Annual Meeting

June 2, 2025

Diakonos Oncology Presents Phase I Analysis of DOC1021 at the 2025 American Academy of Neurology Annual Meeting

April 9, 2025

2025 Spring Symposium hosted by the William T. Shearer Center for Human Immunobiology

March 7, 2025

6th Annual Glioblastoma Drug Development Summit

February 19, 2025

SNO 2024 Presentation: DOC1021 Cell-Based Vaccination as Adjuvant Therapy for Glioblastoma: Phase I Clinical Trial Analysis

November 22, 2024

SITC 2024 Poster: Vaccination by Homologous Antigenic Loading as Adjuvant Therapy for Glioblastoma: Correlation of Immune Response and Early Efficacy Signal with Vaccine Cell Gene Signature

November 9, 2024

CNS 2024 Presentation: Vaccination by Homologous Antigenic Loading as Adjuvant Therapy for Glioblastoma: Analysis of Phase I Results

September 30, 2024

AACR 2024 Poster: Vaccine Immunotherapy by Homologous Antigenic Loading as Adjuvant Therapy for Glioblastoma: Ongoing Phase 1 Analysis

April 9, 2024

Connect with us on social
Twitter LinkedIn

Serving the Patient,
not the Cancer.

    • About
    • Research
    • Science
    • Pipeline
    • News
    • Contact
Expanded Access Program

©2025 Diakonos Oncology Corporation